Formulation Development
RespireRx Enters Collaboration With National Institute for Neurological Disorders & Stroke to Advance its Lead GABAkine Toward Clinical Development
RespireRx Pharmaceuticals Inc. recently announced it has been accepted into the NIH HEAL Initiative NINDS Preclinical Screening Platform for Pain (PSPP) program. The company’s lead…
Ventyx Biosciences Announces Dosing of the First Patient in Phase 2 SERENITY Trial for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ventyx Biosciences, Inc. recently announced the first patient has been dosed in a Phase 2 trial of its selective, allosteric TYK2 inhibitor VTX958 for the…
Bluejay Therapeutics Received Regulatory Clearance to Initiate Clinical Studies of BJT-778 for Treatment of Chronic Hepatitis B & Chronic Hepatitis D
Bluejay Therapeutics recently announced it received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to…
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria & Provides Business Update
Synlogic, Inc. recently announced SYNB1353 has achieved proof of mechanism and positive results in a Phase 1 study in healthy volunteers treated with multiple ascending…
Roivant & Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory & Fibrotic Diseases
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis ….
2023 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
MACHINE LEARNING - Applying Machine Learning Techniques: Gaining Meaningful Life Sciences Insights From Genomics Data
Lucas Glass explains how the predictive capabilities offered by ML solutions can help pharmaceutical and biotech companies shift focus onto additional experiments — providing an opportunity to catch or generate potential options.
ARMED ONCOLYTIC VIRUSES - Instant Messaging Cancer With a TGF-Beta Trap Carrying Oncolytic Adenovirus
Bryan Oronsky, MD, PhD, says cancer is a systemic disease, the eradication of which heavily depends on immune responses. In his opinion, to overcome impaired immune cell function and, hence, to increase the responsiveness to CIs likely requires a 3-in-1 therapy.
DRUG DISCOVERY - Leveraging the Human Gut as a Drug Discovery Tool
Bridget Ann Martell MA, MD, says leveraging a patented technology that uses the human gut as a drug discovery tool has led to a new class of transformative precision therapeutics that disrupt inflammatory disease triggers — gut exclusive microbial metalloprotease inhibitors (GEMMI).
DRUG DELIVERY - Using the IPEG™ Delivery System to Topically Treat Rare Diseases in Dermatology While Limiting Systemic Absorption
Zachary Rome, Jessica Raiz, MPH, and Alan M. Mendelsohn, MD, are advancing innovative clinical research that is evaluating high-potential, low-risk treatments for rare dermatologic diseases using unique topical vehicles combined with established medications that enable the targeted delivery of therapies to the epidermis and dermis while minimizing systemic absorption.
EXECUTIVE INTERVIEW - Ajinomoto Bio-Pharma Services: Giving You the Power to Make
Dr. Nobu Shimba, CEO and President of Ajinomoto Bio-Pharma Services US, discusses the company’s recent areas of focus as well as current plans for expansions.
EXECUTIVE INTERVIEW - Alcami: Unlocking the Potential of Transformative Medicine for 40 Years
Mike Babics, Vice President, Parenteral Services at Alcami, discusses the company’s recent expansions in formulation and analytical development, manufacturing, release testing, and biostorage of clinical and commercial drug products for both solid dosage and parenteral products.
Ryvu Therapeutics & BioNTech Enter Global Collaboration to Develop & Commercialize Immuno-Modulatory Small Molecule Candidates
The companies enter a multi-target research collaboration to develop multiple small molecule programs targeting immune modulation in cancer and potentially other disease areas based on targets selected by BioNTech….
First Wave BioPharma Files INDA for Enhanced Microgranule Delivery Formulation of Adrulipase
Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to initiate in early 2023 with topline clinical data anticipated in the first half of 2023….
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
Aridis Pharmaceuticals, Inc. recently announced the closing of patient enrollment in the multiple ascending dose (MAD) and dose-ranging cohorts in the Phase 2a clinical trial of…
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults With Bipolar I or II Disorder or Schizophrenia
BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, recently announced the first 13 patients have…
Avectas, CCRM & OmniaBio Expand Their Collaboration to Accelerate the Manufacture of Edited iPSCs Using SOLUPORE Technology
Avectas and CCRM, with its subsidiary OmniaBio Inc., have recently announced an expansion of their collaboration, to enable the development of gene-edited induced pluripotent stem….
Immutep Enters Second Clinical Trial Collaboration Agreement With Merck KGaA & Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha & Avelumab to Treat Urothelial Cancer
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumor indications from the combination of eftilagimod alpha (efti) and avelumab (BAVENCIO)….
Context Therapeutics Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Context Therapeutics Inc. recently announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6)…
INmune Bio Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments
INmune Bio, Inc. recently participated in the 15th CTAD Conference in San Francisco November 29 to December 2. “This year’s CTAD is showcasing a potential…
